Saturday, December 16, 2023 3:37:24 PM
First, you know l‘m bringing a lawsuit against you. Thank you for the additional evidence from this morning.
Second, unfortunately you conflate two separate lawsuits. Biosect was encouraging the CEO of US Stem Cell (f/n/a Bioheart) to bring lawsuits against message board posters. There’s a lawsuit involving stock manipulation as attached that does not involve me, but it does involve Biosect. Biosect owes an apology to blinded patients and investors that were wiped out. He probably owes an apology to Dr. Murphy. Read the entire obituary…US Stem Cell was a black mark on an otherwise extraordinary life.
https://casetext.com/case/bioheart-inc-v-peschong
https://www.washingtonpost.com/obituaries/2023/12/06/william-murphy-blood-bags-dies/
Second, unfortunately you conflate two separate lawsuits. Biosect was encouraging the CEO of US Stem Cell (f/n/a Bioheart) to bring lawsuits against message board posters. There’s a lawsuit involving stock manipulation as attached that does not involve me, but it does involve Biosect. Biosect owes an apology to blinded patients and investors that were wiped out. He probably owes an apology to Dr. Murphy. Read the entire obituary…US Stem Cell was a black mark on an otherwise extraordinary life.
https://casetext.com/case/bioheart-inc-v-peschong
https://www.washingtonpost.com/obituaries/2023/12/06/william-murphy-blood-bags-dies/
An FDA statement described U.S. Stem Cell as among “clinics that abuse the trust of patients and endanger their health.” U.S. Stem Cell defended the “efficacy of this protocol” but complied with the judge’s order. The company continued to offer other stem-cell treatments
Note: The company is now bankrupt
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
